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ABSTRACT  
There are limited studies exploring the direct relationship between coconut oil and 
cholesterol concentrations. Research in animals and a few intervention trials suggest that 
coconut oil increases the good cholesterol (high density lipoprotein, HDL) and thus 
reduces the risk of cardiovascular disease. Preliminary research at Arizona State 
University (ASU) has found similar results using coconut oil as a placebo, positive 
changes in HDL cholesterol concentrations were observed.  
The goal of this randomized, double blind, parallel two arm study, was to further 
examine the beneficial effects of a 2g supplement of coconut oil taken each day for 8 
weeks on cholesterol concentrations, specifically the total cholesterol to HDL cholesterol 
ratio, compared to placebo.  
Forty-two healthy adults between 18-40 years of age, exercising less than 150 
minutes each week, non smoking, BMI between 22-35 and not taking any medications 
that could effect blood lipids were recruited from the ListServs at ASU. Participants were 
randomized to receive either a placebo capsule of flour or a coconut oil capsule (Puritan’s 
Pride brand, coconut oil softgels, 2g each) and instructed to take the capsules for 8 weeks. 
Results indicated no significant change in total cholesterol to HDL ratio between 
baseline and 8 weeks in the coconut oil and placebo groups (p=0.369), no significant 
change in HDL (p=0.648), no change in LDL (p=0.247), no change in total cholesterol 
(p=0.216), and no change in triglycerides (p=0.369).  
Blood lipid concentrations were not significantly altered by a 2g/day dosage of 
coconut oil over the course of 8 weeks in healthy adults, and specifically the total 
cholesterol to HDL ratio did not change or improve.  
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Chapter 1 
INTRODUCTION 
The American Heart Association predicts that by 2030 40.5% of the US 
population will have some form of CVD ranging from of heart failure, strokes, 
hypertension or coronary heart disease (1). The cost of direct and indirect medical care 
related to cardiovascular disease was $403.1 billion in 2006 (2). If other factors such as 
obesity and diabetes continue to rise the estimated cost and prevalence of CVD could be 
higher than expected (3). Even with programs such as the National High Blood Pressure 
Education Program and the National Cholesterol Education program designed to help 
lower blood lipid concentrations, reduce smoking, and dietary fat intake, CVD continues 
to be a problem (4,5). Risks involved with developing CVD include smoking, high 
sodium intake, decreased physical activity, high blood pressure, low HDL cholesterol, 
age and gender along with a family history of heart disease (6,7). 
 Desirable concentrations for cholesterol in adults are less than 200mg/dL for total 
cholesterol, less than 100mg/dL for LDL, and 60mg/dL or greater for HDL (8). The total 
cholesterol to high-density lipoprotein ratio, or Castelli index, is a better predictor of 
cardiovascular risk than single measurements of HDL, LDL and total cholesterol. The 
total cholesterol to HDL ratio is considered at risk for men if above 5.0 and above 4.5 for 
women. Higher HDL cholesterol is desirable because it will be divided into the total 
cholesterol and decrease the overall ratio. There is lower cardiovascular risk with a low 
Castelli index ratio (9). An epidemiological study found for every 1mg/dl reduction in 
HDL the risk for coronary disease increases by 2 to 3% (10). A randomized controlled 
double blind study called The Helsinki Heart Study reported that high LDL and 
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triglycerides along with low HDL increased the risk of heart disease (11). There has been 
success in lowering LDL in plasma with drugs like statins, but not much research has 
been done in the way of raising HDL (12). Exercise and a modest intake of alcohol have 
been shown to raise HDL (13,14). HDL is claimed “good cholesterol” because of its 
protective effect and role in reverse cholesterol transport (RCT). During this process 
HDL removes free cholesterol from peripheral tissues, esterifies it via plasma lecithin 
cholesterol acyltransferase (LCAT), which traps cholesterol inside the HDL particle, and 
sends it back to the liver to be excreted into bile (15). HDL also lowered the amount of 
free radicals in blood as well as inflammation from plaque development (16). A cross 
sectional study done by the Heart Research Institute in Australia observed increased 
biomarkers of inflammation like hsCRP and IL-6 along with endothelial activation and 
oxidative stress in subjects with low HDL concentrations compared to the group with 
optimal HDL concentrations (17). CVD can be caused by inflammation and oxidative 
stress (18). Higher HDL concentrations have the potential to remove more LDL 
cholesterol from the arterial wall and decreases atherosclerosis related complications of 
CVD (19). Hence, there is much interest in determining strategies to compliment the 
benefits gained from lowering LDL cholesterol.  
Purpose of Study  
At Arizona State University, preliminary research observed an improvement in 
HDL cholesterol in adults at a much lower dose of coconut oil (2 grams). Coconut oil 
may be a simple and inexpensive way to raise HDL concentration. This study was 
designed to further examine the beneficial effects of a 2g supplement of coconut oil a day 
on HDL cholesterol compared to placebo.  
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Hypothesis  
In free-living healthy adults, 2g/day of coconut oil will decrease the total 
cholesterol to HDL ratio significantly compared to a placebo capsule after an 8-week trial 
with no diet or physical activity modification.  
Limitations  
Participant adherence to protocol and supplement intake. Self reported data is 
prone to error due to recall bias and time constraints. The coconut oil supplement dosage 
of 2g/day could be a limitation. The sample size (n=32) could limit the generalizability of 
the results. The short trial duration (8 weeks) may not show any long term effects of the 
coconut oil supplementation.  
Delimitations  
This test was done on healthy participants and results cannot be generalized to 
those taking lipid-lowering medications. The results derived from this study using 
Puritan’s Pride Brand Coconut oil soft gels may not be generalizable to other coconut oil 
supplements.  
Definition of Terms 
• Cardiovascular disease: Disorders involving the heart and blood vessels.  
• Obese: BMI of 30.0 or higher is considered obese. Having excess body fat that 
could increase health risks.  
• Coconut Oil: Puritan’s Pride 1000mg Rapid Release Softgels.  
• Coronary heart disease: Plaque build up in the coronary arties, hardens and 
restricts blood flow to the heart.  
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• Low density lipoprotein: A molecule made up of lipids and proteins that carries 
cholesterol from the liver to the tissues. Higher concentrations are associated with 
a greater risk of cardiac problems.  
• High density lipoproteins: A molecule made up of lipids and protein that carries 
cholesterol from the tissues to the liver to be excreted in the bile. Higher 
concentrations are associated with a protective effect against cardiac problems. 
• BMI: (Weight (lb) / height (in) x height (in)) x 703). <18.5 is underweight, 18.5-
24.9 is normal, 25.0-9.9 is overweight, and >30 is obese 
• Castelli risk index (CRI-1): Ratio of total cholesterol to HDL cholesterol used to 
predict risk of cardiac health.   
• Triglyceride: Major form of fat stored in the body, made of three fatty acids with 
a glycerol backbone.  
• Statin drugs: Drugs that lower lipid concentrations in the blood and used to 
prevent heart disease. They promote receptor binding of LDL cholesterol.  
• hsCRP: High-sensitivity C-reactive protein is a biomarker of inflammation. Low 
risk for CVD is less than 1.0 mg/L, average risk is between 1.0 to 3.0 mg/L and 
high risk is above 3.0 mg/L.  
• IL-6: A protein and a pro-inflammatory cytokine that increases synthesis and 
secretion of immunoglobulin by B lymphocytes.  
• Hypocaloric diet: Reduced calorie diet, usually between 1,00-1,200 kcal/day.  
• Healthy: No chronic health conditions.  
• Regular smoker: Greater than or equal to 10 cigarettes per day.  
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Chapter 2 
LITERATURE REVIEW 
Cardiovascular disease is caused by complications with the heart and circulatory 
system. CVD is generally caused by a blockage of blood vessels from plaque build up, 
which hardens the arteries and is referred to as coronary artery disease or atherosclerosis. 
This buildup can cause a blood clot, which results in either a stroke, when blood cannot 
get to the brain, or a myocardial infarction, otherwise known as heart attack, when blood 
cannot get to the heart muscles (20).  
 CVD is the number one cause of death among men and women in the United 
States with higher rates for men than women. In 2011, 2,150 Americans died of CVD 
every day. In the U.S. 1 in every 20 deaths in 2011 were attributed to stroke, 1 in every 7 
deaths were caused by coronary heart disease, while around 120,000 people die from 
heart attacks each year (1,21). This disease extends beyond the United States and is 
reported to be the leading cause of death globally (7).  
 Contributors of CVD include, high blood pressure, hypertension, smoking, low 
physical activity, diabetes, high low-density lipoprotein, low high density lipoprotein, 
excessive alcohol intake, age, gender and a family history of CVD or heart disease (6,7).  
Risk Factors for Cardiovascular Disease  
Blood Pressure. The Global Burden of Disease used a population attributable risk 
method to calculate the current rates of high blood pressure around the world and found 
that 54% of stroke, 47% of ischemic heart disease, and 25% of other cardiovascular 
disease resulted from high blood pressure (22). The average blood pressure should 
remain at or under 120/80 mm Hg for adults over the age of 20, and high blood pressure 
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is considered to be higher than 140/90 mm Hg (23). Stroke mortality risk is associated 
with increased blood pressure according to a meta analysis using time dependent 
correction for regression dilution. The findings indicate a 10mm Hg lower usual systolic 
blood pressure or 5mm Hg lower usual diastolic blood pressure would lower the risk of 
stroke by 40% during middle age, 40-89 years (24). High blood pressure causes 
hypertension, which is the main contributing factor for stroke (7). Hypertension affects 
blood vessels by obstructing the flow of blood from the build up of plaque, cholesterol, 
and blood cells as well as creating tears in the artery walls from the high pressure of 
blood flow. When plaque is formed the arteries will narrow and become less elastic, 
creating less blood flow to organs that need the oxygen, leading to coronary artery 
disease or possibly a heart attack if the arteries are blocked all together (25). High blood 
pressure is positively associated with cardiovascular disease risk according to The 
Framingham Heart Study (26).  
Smoking. A major risk for cardiovascular disease is smoking, which has been 
reported to cause 35% of deaths related to CVD. Cigarettes contain toxic compounds like 
nicotine, free radicals and carbon monoxide, at high concentrations can induce 
myocardial infarction and atherosclerosis (27). Nicotine can impair vascular reactivity, 
which is the body adjusting blood flow in the vessels by constricting or dilating them. 
This was tested in a randomized, double-blind, crossover study comparing nicotine nasal 
spray and cigarette smoke, which both declined flow mediated dilation by 10.2 to 6.7 
(nicotine) and 9.4 to 4.3 (cigarette) (28). Chronic smokers exhibit oxidative stress from 
free radicals, which degrade lipids in cells and cause damage (27). Smoking as also been 
linked to oxidation of low-density lipoprotein cholesterol. Yakode et al. experimented 
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with cigarette smoke and found that the superoxide anion component of smoke modified 
LDL enhancing its incorporation into macrophages and creating foam cells, which are 
lipid filled macrophages (29). A meta-analysis of 54 published studies on long term 
cigarette smoking on serum cholesterol concentrations averaged a 3% rise in total 
cholesterol, 9.1% increase in triglycerides, 10.4% increase in very-low-density 
lipoprotein, 1.7% increase in low density lipoprotein, and 5.7% decrease in high density 
lipoprotein cholesterol in smokers (30). These changes provide greater risk of developing  
cardiovascular disease. 
Physical Activity. Physical activity is inversely related with the risk of 
cardiovascular events (31). A meta-analysis of epidemiological studies including 18 
cohort and 5 case control studies examined the relationship between physical activity and 
cardiac events. Highly active individuals had a 25% lower risk of stroke than the low 
active individuals from the combined cohort studies, while the case control studies 
showed a 64% lower risk of stroke from the highly active individuals compared to low 
active (32). A separate cohort study followed 2994 women for 20 years and found 
women who fell beneath the median for exercise capacity had a 3.5 times greater risk of 
cardiovascular mortality (33). Cardiovascular benefits can occur in older adults who start 
exercising somewhere between 30 to 45 minutes of moderate activity each day. A 10 year 
cohort study followed 193 active and 187 non active individuals between the ages of 67 
and 68, and found a -.06 % change in total cholesterol in the active group and a +3.77% 
change in the sedentary, a +9.09% change in HDL cholesterol in the active group and a -
18.18% change in the sedentary group, a -8.41% change in triglycerides in active group 
and +31.82% change in sedentary, and +3.85% change in LDL in active group compared 
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with +6.89% change in sedentary group (34). These results associate physical exercise 
with protection against abnormal lipid concentrations, resulting in less comorbidity from 
cardiovascular events among active adults.  
Diabetes. Diabetes is a disease that affects insulin secretion and impairs glucose 
tolerance, and can increase the likelihood of getting cardiovascular disease. A cohort 
study followed 2,629 Native Americans for 12 years, of those 1,104 had diabetes. 
Baseline data reported systolic and diastolic blood pressure was higher in those with 
diabetes. Elevated blood pressure is a co-morbidly of cardiovascular disease. Diabetes 
increased the risk of cardiovascular disease by 2.9% in this cohort study (35). Diabetes 
can cause damage to blood vessels from malfunctions with the pancreas not producing 
enough insulin to combat glucose broken down from the ingestion of food. A prolonged 
exposure to glucose leads to lipid build up and foam cell formation along with oxidative 
stress. Glucose builds up in the blood and this increases the production of free radicals 
which will cause apoptosis, or premature cell death, as well as reducing nitric oxide 
causing blood vessels to tense and decrease blood flow, individuals are then more 
vulnerable to atherosclerosis and stroke from lack of blood and oxygen. (36,37). Having 
diabetes can increase the risk of developing cardiovascular disease two to four times 
compared to those without (37). 
Family History. Family history of cardiovascular disease is positively associated 
with an increase in risk. A community in California was studied over 9 years to assess the 
prevalence of cardiac risk factors and cardiac death. The researchers looked at different 
ages, degree of relative, and history of heart attack, failure, or stroke. Of 4014 men and 
women, men less than 60 years of age with previous family history of cardiac attacks had 
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higher risk of CVD and ischemic heart disease, since blood pressure and cholesterol were 
also tested to be high. On the other hand women with a family history of CVD were not 
strongly associated with a risk for CVD since both groups (positive family history and 
negative family history) had similar death rates (38). A separate study conducted a 
validated family history study in a retrospective cohort study to assess coronary heart 
disease and hypertension risk in the current population based of family history. When two 
or more 1st degree relatives suffered from one of these diseases, 8% of the family 
population had a relative risk of 3.3 for women and 5.9 for men less than 40 years of age 
(39). A family history of CVD or other heart conditions can lead to increased risk of 
developing the disease for family members.   
Alcohol. Alcohol and its association with CVD is dose dependent. The American 
Stroke Association defines reasonable alcohol consumption as 2 drinks per day for men 
and 1 drink per day for men, and a drink being 12 ounces of beer, 5 ounces of wine, and 
1.25 to 1.5 ounces of liquor (40). The American Diabetic Association guidelines indicate 
that 15 to 30g of alcohol a day is related to a reduced risk of coronary heart disease and 
stroke (41). A study followed women from the Women’s Health Study and men from the 
Physician’s health study, all without hypertension or cardiovascular disease at baseline 
and after a 9.8 year follow up found that light to moderate alcohol intake, which is one 
drink per day, reduced hypertension risk in women, but raised the risk in men. Women 
drinking more than 4 drinks a day had a relative risk of 2.45 for hypertension (42). A 
cross sectional study used data from the National Health and Nutrition Examination 
Survey (NHANES II) to examine HDL cholesterol and alcohol concentrations among the 
United States population. A daily intake of alcohol showed a positive change in HDL of 
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5.1mg/dL, and the regression analyses showed with every 1 g of alcohol consumed 
increased the mean HDL by 0.87 mg/dL (43). The dangers of heavy drinking include a 
higher risk for arrhythmia, high blood pressure, stroke, and heart muscle disease, while 
the benefits of moderate drinking include reducing atherosclerosis and blood clot 
formation (44).  
High Blood Cholesterol. High blood cholesterol is a contributing factor in cardiovascular 
disease. There are two types of molecules that transport cholesterol around in the body. 
There is low-density lipoprotein cholesterol, which carries cholesterol to the arteries 
where it can accumulate and cause atherosclerosis, this is considered the “bad 
cholesterol”. High-density lipoprotein cholesterol, which grabs unesterfied cholesterol 
and transports it back to the liver where it can be excreted in the bile, is considered the 
“good cholesterol” (45). Non-HDL cholesterol is HDL cholesterol subtracted from the 
total cholesterol and indicates the atherogenic cholesterol remaining. Non-HDL 
cholesterol is comprised of LDL, lipoprotein a, intermediate-density lipoprotein (IDL), 
and very low-density lipoprotein (VLDL) (46). Recent studies have suggested that non-
HDL cholesterol and the ratio of total cholesterols to be a more accurate predictor of 
CVD than LDL or HDL cholesterol alone (47). The Strong Heart Study on American 
Indian tribes collected data on diabetic subjects over 9 years and found the non-HDL 
cholesterol had a hazard ratio (HR) of 2.23 for men and 1.80 for women, while the HDL 
cholesterol had a HR of 0.59 in men and 0.97 in women, and LDL cholesterol had an HR 
of 1.71 in men and 1.61 in women. The ratio of total/HDL cholesterol was a better 
indicator of CVD for men with an HR at 2.46, but slightly less than non-HDL cholesterol 
for women with a HR of 1.48. Total/HDL ratio was associated with a higher HR for 
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coronary heart disease, while non-HDL cholesterol was associated with higher HR for 
myocardial infarction (48). When blood cholesterol is elevated it is important to consider 
what exactly is raising it. A total cholesterol concentration above 240 mg/dL is 
considered high, while less than 200 mg/dL is desired. Depending on LDL and HDL 
cholesterol concentrations, the higher total cholesterol could be detrimental. If LDL 
cholesterol is also high around 190 mg/dL this is considered very high and less than 100 
mg/dL is best for health. HDL cholesterol concentration less than 40 mg/dL are 
considered very low and over 60 mg/dL are optimal for health according to the American 
Heart Association (49,130).  
Biomarkers of Cardiovascular Disease 
Lipids. Cellular lipid interactions in plasma, serum, and blood are the traditional 
biomarkers to determine cardiovascular disease risk factors. A fasting blood sample of 
lipid measurements like LDL cholesterol, HDL cholesterol, and triglycerides is preferred 
(50). Total cholesterol to HDL cholesterol ratio has been shown to be a better predictive 
measurement than isolated lipid parameters like LDL and HDL. The reason for this 
relates to the fluctuation in HDL, if HDL is higher and total cholesterol stays the same, 
this will result in a lower ratio, which is considered less risk for CVD, but if HDL 
concentrations were low the ratio to total cholesterol would then be high indicating a 
greater risk of CVD. This is more descriptive than only looking at total cholesterol or 
HDL alone. Primary prevention risk concentrations for men include a total cholesterol to 
HDL cholesterol ratio greater than 5, and greater than 4.5 for women. The ideal ratio for 
men is less than 4.5 and less than 4 for women. Risk concentration of the LDL 
cholesterol to HDL cholesterol ratio for men is greater than 3.5 and greater than 3 for 
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women. The ideal ratio for men is less than 3 and less than 2.5 for women. The ApoB to 
ApoA-I ratio risk concentration for men is greater than 1 and greater than 0.9 for women. 
The ideal ratio is less than 0.9 for men and less than 0.8 for women (9).  
CRP. With atherosclerosis, inflammation can occur from the formation of plaque 
on vessel walls. Endothelial dysfunction can develop and C-reactive protein (CRP), an 
acute phase reactant produced in the liver, is a marker of inflammation. Lipids and 
cholesterol build up in the arteries causing a blockage in blood flow, and vascular 
inflammation (51). A 12-year observational study called The Cardiovascular Health 
Study, including 5888 participants, measured CRP in relation to atherosclerosis detected 
on a carotid ultrasound. Those with a CRP greater than 3 mg/L and had atherosclerosis 
had a 72% increased risk for CVD death (52). CRP was evaluated as a biomarker in death 
risk from cardiac issues in a clinical trial where 917 patients with coronary artery disease 
were followed for an average of 37 months. At a two year follow up those with CRP 
concentrations above 10 mg/L had significantly higher risk of death at 12.6%, compared 
to a 5.1% risk in subjects with CRP concentrations less than 2 mg/L (53). Desirable 
concentrations of CRP are less than 1.0 mg/L, concentrations between 1.0 mg/L and 3.0 
mg/L indicate risk of CVD, while concentrations over 3.0 mg/L are considered high risk 
for CVD (54).  
Blood Pressure. Ideal systolic blood pressure is less than 115 mm Hg, and levels 
higher than 140 mm Hg indicate systemic hypertension. Ideal diastolic blood pressure is 
less than 80 mm Hg, and levels higher than 90 mm Hg also indicate hypertension (55). 
Systolic blood pressure refers to the blood pressure in the arteries, which carry blood 
away from the heart during heart muscle contractions. Diastolic blood pressure refers to 
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the blood pressure between contractions. Abnormal systolic blood pressure is a better 
indicator of cardiovascular disease (56). The auscultatory technique is the typical method 
used to get blood pressure measurements (57).  
 
Cardiovascular Disease Lifestyle Interventions 
As previously discussed, excess alcohol, smoking, and physical activity are major 
risk factors, which are modifiable by lifestyle changes, and studies demonstrate that the 
cessation of smoking, and increasing physical activity while keeping alcohol at a 
moderate intake could lower the risks of cardiovascular disease. (58).  
Smoking Cessation. People who are currently suffering from coronary heart 
disease reduce the risk of repeated heart attacks or other cardiac events by stopping 
smoking (59). A study done by Critchley et al. did a systematic review of prospective 
cohort studies on patients diagnosed with coronary heart disease and the association 
between smoking cessation rates. From 665 articles, relative risk of mortality dropped by 
36% among patients who quit smoking with existing coronary heart disease compared to 
those who did not quit (60).  
Exercise. The Centers for Disease Control and Prevention and the American 
College of Sports Medicine recommend adults should exercise 30 minutes or more each 
day doing moderate physical activity such as walking briskly, swimming, and cycling 
(61). A report on male residents in the Netherlands, between that ages of 35-69, 
compared a high activity group to low activity and the relative risk for coronary heart 
disease ranged from 1.2 to 2.3, vigorous exercise compared to no vigorous exercise, and a 
 14 
relative risk of 1.1 to 2.1, moderate exercise compared to occasional low activity (62). 
Increasing physical activity reduces the risk of coronary heart disease.  
Decreasing Alcohol Intake. Decreasing alcohol consumption from excessive 
amounts is another way to avoid risks of developing cardiac problems. Corrao and his 
colleges examined epidemiological articles from 1966 to 1988, and 51 were selected for a 
meta-analysis to which they found the average relative risk associated with drinking 89 
grams or more of alcohol per day was around 1.05 (63). Heavy drinkers are at higher risk 
of acquiring high blood pressure, heart failure, cardiac arrhythmia, and stroke and the 
American Heart Association recommends the average intake be 1-2 drinks for men and 1 
drink for women each day, and to keep it in moderation (64).  
Losing Weight. Losing excess weight can be another key factor in reducing the 
risk of CVD. Obese patients with a BMI over 30, generally have higher cardiac output 
and workload and this pressure cause left ventricular chamber dilation and have other 
negative effects on diastolic and systolic blood pressure from fat, especially intra 
abdominal fat (36,65). The American Heart Association reports that with every 10kg 
increase in body weight, systolic blood pressure can increase 3.0-mm Hg, and diastolic 
blood pressure can increase 2.3-mm HG, and this increases coronary heart disease risk by 
an estimate of 12% and stroke risk by 24% (66). An individual in the overweight or obese 
category is recommended to consider losing weight to reduce some risks of 
cardiovascular disease.  
Dietary Modifications. The American Heart Association stresses the importance 
of a healthy diet to combat heart problems. Nutrient dense foods are recommended, those 
full of vitamins and minerals. A colorful variety of fruits and vegetables should be 
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included in the diet along with whole grain options, nuts, low fat dairy products, and a 
limited amount of trans fats, sodium, and sweetened drinks (67).  
The DASH Diet. One diet the American Heart Association recommends is the 
DASH diet, which stands for Dietary Approaches to Stop Hypertension, which is 
considered a heart healthy diet for handling high blood pressure and helping to reduce 
any risks of stroke and heart attack (67,68). The DASH diet is intended to lower blood 
pressure that is already high and recommends a diet low in saturated fat, cholesterol, and 
total fat, red meats, sweets, and sugared beverages, while consuming higher amounts of 
vegetables, fruits, whole grains, poultry, fish, nuts, and low-fat dairy. The DASH diet 
eating plan differs depending on if the individual is trying to lose weight or not, but some 
tips to help is to use fruit as a dessert, choosing whole grain foods over white, and using 
half the butter or fat currently being used. Another focus of the DASH diet includes using 
less sodium to keep blood pressure from increasing. Consuming six grams, about one 
teaspoon, or less is recommended. Buying food labeled “no added salt” as well as 
cooking meals like rice and pasta without salt is advised. Replacing salt with spices is 
another way to keep flavor while consuming less sodium (69). The DASH diet held a 
randomized controlled trial where participants with untreated systolic blood pressure 
lower than 160mm Hg and diastolic blood pressure of 80-95 mm Hg, were fed a 
controlled diet of either high fruits and vegetables or DASH diet recommendations over 
an 8 week period. Sodium was kept at 3000 mg/day in both diets. The DASH diet showed 
decreases in systolic blood pressure by -3.5 mm Hg in normal participants and -11.6 
mmHg in hypertensive participants, and decreased diastolic blood pressure by -2.2 mm 
Hg in normal participants and -5.3 mm Hg in hypertensive participants (70).  
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The Ornish Diet. The Ornish diet focuses on low fat intake, such as full fat dairy 
and red meat, and increasing complex carbohydrates like fruits, vegetables, whole grains, 
soy products, non fat dairy, and legumes, while including some fish, nuts, and seeds. 
Consuming omega 3 fatty acid is another recommendation in food or supplement form. 
The Ornish diet breakdown of calories includes no more than 10% of calories from fat, 
10 milligrams of cholesterol a day, consuming sugar and sodium in moderation, and 
getting protein from plant based sources (71). One randomized controlled trial took 
patients with coronary artery disease and split them up into the experimental group 
involving an Ornish diet with less than 5 mg/d cholesterol, less than 10% of total kcal 
from fat, with mild exercise and stress management with the control group getting the 
usual care in an outpatient setting. Cardiac positron emission tomographic scans were 
taken after 5 years and most participants in the experimental group stopped the 
progression of coronary heart disease (72,73). The experimental group showed 
improvements in percent diameter stenosis, stenosis flow reserve, and lumen diameter 
and the percentage of patients with significant changes in size and severity of myocardial 
perfusion abnormalities with 99% of patients having better or no change compared to 
55% of the control group. There was also a significant change in total cholesterol 
between the experimental group and baseline data (-50 mg/dL ± 37), and the control 
group and baseline data (-20 mg/dL ± 43) (73). The Ornish diet aims to reverse the 
progression of heart disease by emphasizing real foods high in complex carbohydrates, 
healthy fats, and plant-based proteins.  
The Vegetarian Diet. The American Dietetic Association supports research 
showing vegetarian diets are associated with lower risk of ischemic heart disease, lowers 
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LDL cholesterol, blood pressure, and hypertension. The vegetarian diet is one excluding 
all forms of meat including seafood (74). A study measuring antioxidant status, oxidative 
stress, and inflammation found vegetarians (individuals who had been vegetarians for 
over 5 years), had a combined difference of -0.29 mm/L compared to the non vegetarians. 
C-reactive protein was also -0.53 mg/L less in vegetarians than non vegetarians (75). 
Plant based foods like fruits and vegetables have dietary fiber, flavonoids, and 
antioxidants, also associated with reducing CVD risk. The Nurses’ Health Study and the 
Health Professionals’ Follow up Study examined the relationship between vegetable 
intake and multivariate relative risks of CVD. The relative risks (RRs) of all vegetable 
intake is 0.82 for CAD and 0.90 for stroke, and all fruit intake is 0.80 for CAD and 0.69 
for stroke. Intake is dose responsive and at least 8 servings of fruit and vegetables a day is 
associated with the lowest risk for CAD (76). Clinical studies have also been done on the 
cardioprotective effects of nuts, another vegetarian food. One six week trial had 
participants consuming walnuts (41-56 g/day) and found that the change in LDL 
cholesterol decreased by -22.0 mg/dL, and total cholesterol decreased from -24.7 mg/dL, 
and Triglycerides decreased by -4.64 mg/dL (72). The protective effects of a vegetarian 
diet are due to a variety of plant based foods containing nutrients like omega 3 fatty 
acids, antioxidants, phytochemicals, fiber, folate, and other vitamins and minerals in 
fruits, vegetables, nuts, and whole grains (76).  
Diet Comparisons. The Institute of Medicine and the Adult Treatment Panel III 
agree that saturated fat should be reduced to prevent CVD, but replacing it with a specific 
macronutrient has not been suggested yet. A couple diets have been recommended such 
as diets rich in monounsaturated fats, which have been shown to raise HDL cholesterol 
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and reduce triglycerides, diets rich in protein to lower blood pressure, and diets high in 
carbohydrates like DASH to reduce blood pressure and LDL cholesterol (78). The 
Optimal Macronutrient Intake Trial to Prevent Heart Disease (OmniHeart) conduced an 
18 week randomized clinical crossover feeding trial in healthy adults over 30 years with a 
systolic blood pressure between 120-159 mm Hg or a diastolic blood pressure between 
80-99 mm Hg. The three diets were set up to have distinguishable differences in 
macronutrients. Carbohydrates in the carbohydrate diet composed 55% of kcal, protein in 
the protein diet composed 25% of kcal, and unsaturated fat in the unsaturated fat diet 
composed 31% of total kcal. The protein diet had over half of the protein coming from 
plant-based sources such as nuts, soy, seeds, grains, and legumes. The unsaturated diet 
used oils like canola, olive, and safflower along with nuts and seeds to meet the percent 
in kcal needed. Results showed that compared with the high carbohydrate diet, the high 
protein diet decreased mean systolic blood pressure by 1.4 mm Hg in adults without 
hypertension and decreased by -3.5 mm Hg in those with hypertension. LDL cholesterol 
also decreased by -3.3 mg/dL, and triglycerides decreased by -15.7 mg/dL. The 
unsaturated fat diet compared to the carbohydrate diet decreased systolic blood pressure 
by -1.3 mm Hg in those without hypertension and decreased by -2.9 with hypertension, 
while also increasing HDL cholesterol by +1.1 mg/dL. Risk factor changes were also 
analyzed using the Framingham risk equation and Prospective Cardiovascular Munster 
risk equation to calculate the average 10 year risk of coronary heart disease on each diet. 
The CHD risk percent average between men and women in the protein diet reduced by -
5.8% compared to the carbohydrate diet, and the unsaturated fat diet reduced by -4.2% 
compared to the carbohydrate diet (78). Based on this data, partial replacement of 
 19 
carbohydrates with either monounsaturated fat or protein could help improve blood lipids 
and reduce the risk of cardiovascular disease.  
Functional Foods and Supplements. The cardiovascular effects of certain 
supplements and functional foods have been researched in hopes of finding a substance 
helpful in reducing heart disease risk. The following non-pharmaceuticals listed in table 1 
describe the variety of compounds and the mechanisms used to improve lipid parameters.  
Table I: Non Pharmaceuticals for Cardiovascular Disease 
 
Non 
Pharmaceuticals 
Compound Mechanism Studies 
Coenzyme  Q10 A component of the 
mitochondrial 
electron transport 
chain for ATP 
synthesis, generated 
from tissues.  It is 
carried by LDL 
particles. It is 
obtained from 
dietary sources like 
fruits, vegetables 
and meat (79).  
Coenzyme Q10 is 
an antioxidant that 
acts on oxidative 
stress from 
atherosclerosis. It 
acts by removing 
oxygen radicals and 
reducing tocopheryl 
radicals back to 
tocopherol. It is 
reported to help 
prevent LDL 
oxidation and 
improves energy 
production in 
cardiac tissue (79).  
A meta-analysis by 
Soja and Morensten 
in 1997 reported 
significant 
improvements, from 
controlled clinical 
trials, in stroke 
volume and cardiac 
output in subjects 
taking CoQ10 
compared to the 
placebo group (79).  
Green Tea  Catechins is a 
polyphenolic 
compound found in 
green tea (80).  
Catechins is an 
antioxidant with 
lipid lowering 
effects by inhibiting 
key enzymes needed 
in lipid biosynthesis. 
They prevent 
vascular 
inflammation by 
suppressing 
leukocyte 
attachment to 
endothelium (80).  
A cross sectional 
study found a 
reduction in 
hypertension risk by 
46% was associated 
with drinking 120-
599 ml/day of green 
tea for a year and a 
65% reduction in 
those drinking over 
600ml/day (81).  
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Pomegranate 
Extract 
The main 
antioxidant 
polyphenols in 
pomegranate juice 
are elagitannins and 
anthocyanins (82).  
Pomegranate juice 
increases 
antioxidants 
concentration in 
serum and decreases 
lipid peroxidation, 
inflammation, and 
systolic blood 
pressure (82).  
A clinical trial in 
which diabetic 
patients were given 
40g of pomegranate 
juice a day for 8 
weeks had 
significant drops in 
total cholesterol and 
LDL cholesterol 
(82).  
Red Wine  Red wine contains 
polyphenol 
compounds with 
antioxidants (83).  
The synthesis of 
endothelin-1, which 
causes 
vasoconstriction, is 
inhibited by red 
wine, which lowers 
the risk for coronary 
heart disease (83).  
A meta-analysis of 
13 studies found a 
32% reduced risk in 
atherosclerosis with 
groups consuming 
red wine compared 
to a 22% reduced 
risk from those 
consuming beer 
(84).  
Omega 3 Fatty 
Acids 
Polyunsaturated 
fatty acids typically 
found in plant, nut 
or seafood oils 12. 
Seafood is 
composed of 
eicosapentaenoic 
acid (EPA) and 
docosahexaenoic 
acid (DHA), while 
nuts are composed 
of alpha-linoleic 
acid (ALA) (85). 
The DHA can 
inhibit platelet 
aggregation by 
reducing a specific 
platelet receptor for 
its ligand. The EPA 
can replace 
arachidonic acid, 
known to cause 
inflammatory 
reactions, in 
phospholipid 
bilayers (85). 
A clinical trial 
investigated 11,324 
patients with recent 
myocardial 
infarction. Patients 
were given either 1g 
of omega 3 fatty 
acid, 300mg of 
vitamin E, or both in 
supplement form. 
After 3.5 there was 
a 15% decrease in 
risk in in total death 
and non fatal 
myocardial and 
stroke in the omega 
3 fatty acid group 
(P<0.02) (86). 
Garlic Allium sativa is a 
plant with flat 
leaves around a 
flower. The stalk 
that grows from the 
flower bulb is used 
as food. It’s active 
The sulfur 
compounds have the 
ability to reduce 
fatty substance build 
up in the blood, 
which helps 
maintain normal 
One placebo 
controlled study had 
subjects consume 
500 mg of garlic 
powder each day 
over 4 months. 
Subjects consuming 
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components are 
amino acids called 
alliin and an enzyme 
called allinase, 
which eventually 
turns to sulfur 
compounds, along 
with trace minerals 
like copper, 
magnesium, 
selenium, iron, and 
zinc (87). 
blood pressure. It 
can inhibit HMC 
Co-A reductase, 
decreasing 
cholesterol 
synthesis. A sulfur 
compound called 
ajoene makes the 
platelets slippery, 
not as likely to stick 
together in the blood 
(87,88).  
garlic with a higher 
baseline total 
cholesterol around 
250-300 mg/dL, 
reduced these 
concentrations by 
11% with an 
additional decrease 
in triacylglycerol 
concentrations by 
15% (89). 
Pharmaceutical Interventions. Cholesterol medication is another option to help 
control elevated concentrations of blood lipids in order to decrease cardiovascular disease 
risk. There are different categories such as statins, fibrates, niacin, bile acid binding 
resins, and cholesterol absorption inhibitors.  
Statin Drugs. Statin drugs, also called HMG-CoA reductase inhibitors, and are 
intended to lower LDL and triglycerides in plasma. HMG-CoA reductase is an enzyme 
that helps transform HMG-CoA to mevalonate and triggers the synthesis of cholesterol 
and coenzyme Q10. Stains work by latching on to the HMG-CoA reductase and blocking 
its ability to transform HMG-CoA to mevalonate and this decreases the output of 
cholesterol. The decreased cholesterol activates protease, which cleaves sterol regulatory 
element binding proteins (SREBP) from the endoplasmic reticulum, which moves to the 
nucleus. From there it up-regulates the expression of the LDL receptor gene and increases 
the LDL receptor expression, increasing the receptor-mediated endocytosis of LDL and 
overall decreasing LDL cholesterol production in the liver and leading to less LDL 
cholesterol in the bloodstream (90,91). Clinical trials have been done to show the benefits 
of statins in lowering LDL cholesterol. Patients with hypercholesterolemia and 
hypertriglyceridemia have shown benefit from using statins. One randomized, double 
 22 
blind parallel study looked at the effects of 80mg/day dose of simvastatin, a type of statin 
drug, on 521 hypercholesterolemia patients in 24 weeks. From baseline data LDL 
cholesterol decreased by a mean of 46%, total cholesterol decreased by a mean of 35%, 
triglycerides decreased by a mean of 25%, and HDL cholesterol increased by a mean of 
6.1%. Statins also lower triglycerides and raise HDL slightly (92). A separate double 
blind study dispersed either 40mg of pravastatin, a type of statin drug, or a placebo to 
4159 men and women with myocardial infarction and over the course of five years stroke 
incidents were lower by 31% among the group taking the statin compared to placebo, a 
difference of 78 to 54 patients. Death from coronary heart disease occurred in only 96 
patients in the pravastatin group compared to the 119 patients in the placebo group as 
well as nonfatal myocardial infarction occurred in 182 patients in the pravastatin group 
compared with 231 patients in the placebo group (93). The FDA warns about the possible 
side effects of statins, such as cognitive impairment, increased blood sugar levels, and the 
most reported, muscle damage (94).   
Fibrates. Fibrates are another lipid lowering drug intended to work on fatty acids 
and decreasing triglycerides. Fibrates trigger the peroxisome proliferator-activated 
receptors (PPARs) to induce the formation of a nuclear transcription complex, which 
ends up increasing HDL synthesis and lipoprotein lipase. They also prompt the uptake of 
fatty acid and catabolism by the beta-oxidation pathways, which end up reducing fatty 
acid and triglyceride synthesis. Fibrates increase apoA-I and apoA-II along with HDL 
(95). Fibrates are the first drug selected for hypertriglyceridemia since triglycerides are 
significantly decreased after use. A clinical study examined 1000 patients with different 
types of hyperlipoproteinemia and a drug called bezafibrate, a form of fibrate medication, 
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on blood lipid concentrations. A placebo group was compared to the bezafibrate group, 
the median % change in total cholesterol was -14.6% in the benzafibrate group and only 
dropped -0.8% in the placebo group (among hyperlipoproteinemia patients with type IIa). 
The median % change in total triglycerides in the bezafibrate group was -29.9%, while 
the placebo had a -2.1% drop. LDL cholesterol fell -16.4% in the bezafibrate group and -
0.4% in the placebo group. The HDL cholesterol to total cholesterol ratio increased 
+31.3% in the bezafibrate group compared to the +0.2% increase in the placebo group. 
This study suggests that fibrates are a safe and effective medication to improve lipid and 
lipoprotein concentrations (96). Fibrates work by increasing the clearance of very low-
density lipoprotein cholesterol and reducing cholesterol synthesis in the liver, effects that 
have been shown to help decrease coronary heart disease. A clinical trial testing the effect 
of gemfibrozil, a type of fibrate drug, on 700 CHD patients with type 2 diabetes and low 
HDL cholesterol compared blood lipids concentrations after a five year period and found 
triglycerides decreased by 24% and HDL increased by 7.5% with no significant change in 
LDL and an overall decrease in coronary heart disease by 22% (97). Rhabdomyolysis is a 
possible side effect of taking fibrates. A study of 132 men and 145 women observed 
22.8% were experiencing adverse skin reactions, 9.8% had GI diseases like pancreatitis, 
and 6% had nervous system disorders (98). 
Niacin. Niacin is known to modify lipoproteins and is used for the treatment of 
dyslipidemia and cardiovascular disease. Also called nicotinic acid or vitamin B3 and is 
found in food and prescriptions. It was the first medication used for lipid regulation and it 
has been shown to successfully lower total cholesterol, LDL cholesterol (including small 
dense LDL), total triglycerides, and lipoprotein-a (99). Niacin works by inhibiting 
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triglyceride lipolysis in the adipose tissue, thus reducing free fatty acids. It also hinders 
hepatocyte diacylglycerol acyltransferase, which causes an increase in apolipoprotein-B 
break down and reduces the secretion of VLDL and LDL cholesterol. Niacin can also 
increase lipoprotein-A1, which is a component of HDL (100,101). The Coronary Drug 
Project tested the effects of niacin compared with a placebo in 8,341 men using a dosage 
of 2000 mg of niacin over the course of 6.2 average years. The niacin group experienced 
26% less incidences of myocardial infarction and 24% less cerebrovascular events. Total 
mortality was 11% less than the placebo group at a 15 year follow up (102). A 
randomized, double blind, placebo controlled trial by Morgan et al. compared 122 
patients in three separate groups, placebo group, 1000 mg/day Niaspan (an extended 
release capsule of niacin) and 2000 mg/day Niaspan. Over the 12 week trial Niaspan 
reduced low-density lipoprotein by 6% in the 1000 mg/day group and 14% in the 2000 
mg/day group and high-density lipoprotein increased by 17% and 23% for the 1000 
mg/day group and 2000 mg/day group. The placebo group showed no significant 
improvements in lipids except for a small increase in HDL by 4%. Serum lipoprotein-a 
and triglyceride concentrations decreased by 27% and 29% in the 2000 mg/day group as 
well (103). Some negative effects of niacin use include flushing, where the skin becomes 
warm, usually in the face, possible increases in blood sugar concentrations, as well as 
gastrointestinal discomfort. A randomized controlled study by Mills et al. looked at these 
symptoms in a 500mg supplement of niacin in 68 men and women, 33 in niacin group, 35 
in placebo group, and found that all 33 participants in the niacin group experienced 
flushing within a mean time of 18.2 minutes after ingestion. Gastrointestinal issues 
occurred in 30% of the volunteers (104). Tingling and itching sensations can also occur. 
 25 
Since flushing is the most common side effect of niacin, alternatives like statin drugs are 
the more popular form of cholesterol lowering medication (105).  
Bile Acid Binding Resin. Bile acid binding resin (BAR) is an alternative 
treatment for hyperlipidemia and has been used for over 40 years. BAR works by 
absorbing bile acids, in the lumen of the intestines and increases the excretion of 
cholesterol in fecal matter. In both human and rodent trials BAR was shown to improve 
glucagon-like peptide-1 (GLP-1) secretion, which is a neuropeptide that helps slow down 
gastric emptying and increases satiety (106,107). A study by Glueck et al. observed the 
cholesterol change in children heterozygous for familial hypercholesterolemia taking a 
type of bile acid resin called cholestyramine over the course of 5 years. There was a 
12.5% decrease in total cholesterol concentration in 32 children taking resins (108). 
Cholestyramine is another generic name for bile acid binding resin and helps move more 
cholesterol through the liver to be excreted in the fecal matter by binding to bile acids in 
the gastrointestinal tract. Nine participants with primary hypercholesteremia were 
followed for four years and given cholestyramine and total serum cholesterol was shown 
to decrease in eight out of nine participants. It was also observed that cholesterol would 
rise again once cholestyramine administration was interrupted (109). Some side effects of 
bile acid resins include heartburn, gas, upset stomach, and constipation. They can also 
interfere with medications treating low blood sugar (110).   
Cholesterol Metabolism, Measurements, and Biomarkers 
Cholesterol is a waxy compound found in the tissues of animals and humans and 
is mainly produced in the liver. Cholesterol is acquired through food and diet in dairy, 
meat, fish, poultry and oil products even though the body makes enough cholesterol 
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endogenously to meet its needs. It is necessary for the absorption of fat soluble vitamins 
like A, D, E, and K, and production of steroid hormones. Around 300 to 400mg of 
cholesterol comes from dietary intake each day, while the rest is synthesized in the liver 
(111). Cholesterol is made from the conversion of three acetyl CoAs into 3-hydroxy-3-
methylglutaryl-CoA or HMG-CoA, which is then converted to mevalonate by HMG-CoA 
reductase, then isopentenyl pyrophosphate (IPP), losing carbon dioxide and converting to 
squalene, then finally cholesterol (112).  
Lipoproteins. Lipoproteins contain varying amounts of cholesterol and transport it 
throughout the body. Lipoproteins consist of high-density lipoprotein HDL, low-density 
lipoprotein LDL, very low-density lipoprotein VLDL, intermediate density lipoprotein 
IDL, and chylomicrons. HDL is made in the liver and then moves through the blood in 
tissues, absorbing unesterfied cholesterol to transport it back to the liver for excretion. 
VLDL is formed mainly in the liver and partially in the intestines and transports new 
triglycerides and lipids from the liver to adipose tissues throughout the body. LDL is 
formed in the blood from VLDL and becomes this when triglycerides are removed from 
the VLDL. LDL then transports cholesterol from the liver to the blood and tissues in the 
body. LDLs are made up of higher amounts of cholesterol and contain smaller amounts 
of protein. HDL is the opposite containing high amounts of protein and little cholesterol. 
Chylomicrons are formed in the gastrointestinal tract, transported to the lymph system 
and then to the blood, transporting dietary fat into the blood, and tissues throughout the 
body. Triglycerides are embedded in the chylomicron and once they are removed the 
remains of the chylomicron are absorbed by the liver (110,91,113).   
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Apoproteins. Lipoproteins contain different fractions of triglycerides, cholesterol, 
phospholipids, and proteins called apoproteins (A,B,C,D,E). Apoproteins help the 
enzymes responsible for lipoprotein break down and metabolism (114). Apolipoprotein 
(apo) B-100 represents a majority of the protein in LDL and is also in IDL and VLDL. 
Apo B-48 is made in the intestines and is the major protein on chylomicrons (111). 
Apolipoprotein A-I is the major protein in HDL and in charge of initiating reverse 
cholesterol transport. A high ratio of Apo B to Apo A-I results in more cholesterol 
circulating through the blood, which could increase atherosclerosis risk (9). Apo C-II is 
needed for lipoprotein lipase activation, which hydrolyzes triglycerides, converting 
chylomicrons into chylomicron remnants and VLDL to IDL, which ends up being LDL 
(115).  
Triglycerides. Triglycerides are a type of lipid composed of three fatty acids 
attached to one glycerol backbone. They mainly exist as fat in food sources or storage in 
fatty tissues and vary depending on the length of fatty acid chain and degree of saturation 
and are synthesized by the liver or intestines for energy (116). Triglycerides from dietary 
fat are incorporated into chylomicrons and transported in the blood to tissues. Daily 
intake ranges from 70 to 150g (117). Triglycerides are considered a marker for heart 
disease risk. Normal triglyceride concentrations should be less than 150 mg/dL and the 
American Heart Association recommends a fasting concentration of 100 mg/dL for 
increased heart and blood vessel protection. The highest risk for acute pancreatitis is 
triglyceride concentrations above 500 mg/dL (118).  
Fatty Acids. Fatty acids are the basic building blocks of fats and are considered 
either saturated, monounsaturated, or polyunsaturated (116). According to chain length 
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fatty acids are divided into three categories, short chain fatty acids, which are 2-6 carbon 
atoms, medium chain fatty acids, which are 8-12 carbon atoms, and long chain fatty 
acids, which are 14 carbon atoms or more. According to the degree of saturation and the 
presence of a double bond or not, fat is classified as either saturated or unsaturated. 
Saturated fatty acids have no double bond and have many hydrogens attached. 
Unsaturated fatty acids have one or more double bonds and differ by isomers being either 
cis or trans where hydrogens are either on the same side or opposite sides of the chain. 
Long chain fatty acids are broken down into saturated and unsaturated (119). Saturated 
fats consist of tropical oils like coconut and palm kernel oil, animal fats, butter and milk 
(120). Unsaturated fats are further divided into polyunsaturated fats and monounsaturated 
fats. Polyunsaturated fats consist of omega 3 fatty acids, some common ones being 
eicosapentanoic acid (EPA) from sources like fish as well as docosahexanoic acid (DHA) 
also from fish sources as well as alpha linolenic acid (ALA), which comes from plant 
sources like walnuts, soybeans and flaxseeds. Omega 6 fatty acids generally come from 
sources like vegetables oils such as corn or safflower (121). They can decrease LDL 
cholesterol and are less resistant to oxidation. Monounsaturated fats contain omega 9 
fatty acids and are found in food sources like nuts, olives, and avocados (122). Omega 9 
fatty acids can decreased LDL cholesterol, but are more resistant to oxidation than 
polyunsaturated fatty acids. In the U.S. omega 6 fatty acids are the most commonly 
consumed fatty acids because of the popularity of vegetable oils, but the body lacks the 
enzymes needed to convert omega 6 fatty acids into omega 3 fatty acids (123). Omega is 
the last letter in the Greek alphabet and refers to the last carbon atom in the fatty acid 
chain. The omega fatty acid gets its name based on the position of the first unsaturation. 
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Omega 3 would indicate that the first double bond is at the third carbon-carbon bond 
from the methyl end of the fatty acid (124). 
Trans Fatty Acids. Trans fatty acids are artificially processed plant oils that 
involve the hydrogenation of unsaturated fatty acids where there is a change in the 
isomerism of the double bond in the chain length and cis is switched to trans to produce a 
product that resist rancidity and has a higher melting point. Trans fatty acids became the 
popular alternative to tropical fats like coconut oil since food industries desired solid fats 
with a longer shelf life (125). There is an association between trans fatty acids and 
negative blood lipid parameters due to studies that tested the effects of dietary trans fatty 
acids on cholesterol concentrations. A study done by Mensink et al. placed 34 women 
and 25 men on three mixed diets with 10% of daily energy intake coming from either 
saturated fatty acids, trans isomers of omega 9 fatty acid (oleic), or omega 9 fatty acid in 
the cis form. The ratio of total cholesterol to HDL cholesterol in the trans isomers of 
omega 9 fatty acid diet changed by an increase of +11.99 mg/dL, while the saturated fatty 
acid diet increased +0.77 mg/dL, and the cis isomers of omega 9 fatty acid diet decreased 
-13.15 mg/dL. Trans fatty acids diet also raised LDL cholesterol by +14.31 mg/dL and 
lowered HDL cholesterol by -6.57 mg/dL compared to the cis isomers omega 9 fatty acid 
diet (125). Based on a meta analysis of prospective studies there is a 24-32% increased 
risk of myocardial infarction and coronary heart disease death with every 2% increase in 
trans fatty acid consumption when replacing either carbohydrates, short chain fatty acids, 
cis medium chain fatty acids and cis polyunsaturated fatty acids (126). In 2013 the FDA 
stated partially hydrogenated oils were no longer generally recognized as safe and should 
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not be used in the production of food. The FDA released June 2015 a statement giving 
food manufacturers three years to remove all trans fats from their products (127). 
Cholesterol Metabolism. The exogenous pathway of cholesterol starts with fat 
and cholesterol absorption in the gut, and from there apoproteins, unesterfied cholesterol, 
and phospholipids cling to the newly absorbed triglyceride or cholesterol and are 
packaged into a chylomicron. This chylomicron will then move through the lymph 
system in the intestine and enter the blood where it then latches on to the adipose and 
skeletal muscle tissue cells. Lipoprotein lipase reacts with the chylomicron releasing the 
free fatty acids, which then move through the endothelial cells and end up stored in the 
adipose and skeletal muscle tissues. Once the free fatty acids and triglycerides are 
removed the remnant chylomicron particle, made up of apoproteins binds to the liver 
cells to be broken down by lysosomes. Empty HDL is another product of this process and 
these can pick up LDL and phospholipids from peripheral tissues. The chylomicron 
remnant travels to the liver where apoE binds to the remnant receptor and at this point 
cholesterol is free and the liver could excrete it in the bile or package it into VLDL to be 
sent back to the tissues. The endogenous pathway starts at the liver where triglycerides 
are packaged on to VLDL. VLDL’s then travel through blood to peripheral tissues and 
release as glycerol and fatty acids at muscle and adipose tissue. When this happens the 
VLDL becomes smaller and is now called IDL. IDL are absorbed into the liver from the 
blood and are broken down by hepatic lipase, apoproteins break off and cholesterol esters 
are traded for triglycerides and LDL is formed. LDL contains high amounts of cholesterol 
and is absorbed by peripheral tissue by binding to LDL receptors, while extra LDL is 
absorbed by the liver (114,127,128). Reverse cholesterol transport occurs when there is 
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excess cholesterol in the peripheral tissues and HDL interacts with ATP binding cassette 
transporter A1 (ABCA1) and takes cholesterol back to the liver (129). Cholesterol is 
excreted in the bile as free cholesterol or bile salts (128).  
Measuring Cholesterol. Measuring cholesterol is an important resource for 
collecting heart health information. Cholesterol concentrations fall within a range 
between desirable and high risk. Cholesterol and triglyceride concentrations vary 
depending on the meal consumed.  
Table II: Cholesterol Measurements (110,130) 
 
 
Coconut Oil  
Coconuts (C. nucifera) have multiple nutritious components such as the copra or 
dried kernel, which oil is extracted from, the wet meat or kernel that is sweet and used in 
cooking, and water which contains vitamin B, vitamin C, nicotinic acid B3, folic acid, 
and other micronutrients that make it desirable (131). Coconut oil has a melting point of 
 Desirable Above 
Optimal 
Somewhat 
High 
High  Very 
High 
LDL 
Cholesterol 
<100 mg/dL 100-129 
mg/dL 
130-159 
mg/dL 
160-189 
mg/dL 
>190 
mg/dL 
Triglycerides  <150 mg/dL  150-199 
mg/dL 
200-499 
mg/dL 
>500 
mg/dL 
HDL 
Cholesterol 
> 60 mg/dL  40-59 mg/dL  <40 
mg/dL 
Total 
Cholesterol 
<200 mg/dL  200-239 
mg/dL 
 > 240 
mg/dL 
Total 
Cholesterol/ 
HDL Ratio 
3.5:1     
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23-26 degrees Celsius, which makes it solid at room temperature below 73 degrees (132). 
Virgin coconut oil has a natural coconut aroma, is colorless, and resists rancidity (133).  
Extraction Methods. The dry process of collecting coconut oil is made from 
copra, where is it exposed to high heat or sunlight for several days and the end product is 
called copra oil. The outer shell from a fallen or manually picked nut is split and the 
endosperm meat is then dried. Drying the meat can be done in the sun or in an oven. A 
screw press is first used to expel the copra, then n-Hexane is used to extract the oil (132). 
The wet process involves extracting oil from coconut milk under controlled settings and 
heat and the end product is called virgin coconut oil (134). There are multiple means of 
separating the oil from water, such as fermentation, refrigeration, enzyme action, 
centrifugal separation, and micro-expelling (133).  
Composition. Virgin coconut oil is a mixture of free fatty acids, 85% 
triglycerides, 7% diglycerides, and 3% monoglycerides (135). Coconut oil is a saturated 
fat mainly made up of medium chain fatty acids (MCFAs), around 65%, which are 
comprised of 8-12 carbons, and is more water soluble than other vegetables oils 
(131,135). The fatty acid breakdown of coconut oil extracted from the seed kernel of 
Cocos nucifera is 44.6g per 100g 12:0 medium chain, saturated fatty acid (lauric acid), 
16.8g per 100g of 14:0 long chain, saturated fatty acid (myristic acid), and 8.2g per 100g 
of 16:0 long chain, saturated fatty acid (palmitic acid) (136) Marina et al. looked at ten 
virgin coconut oil samples from Malaysia and Indonesia and compared them with refined 
coconut oil. These samples were composed of caprylic, caproic, capric, lauric, myristic, 
stearic, palmitic, and linoleic acid (136). Lauric acid made up 46 to 53% between the 
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samples of both virgin coconut oil and refined coconut oil while capric fatty acid made 
up 0.52 to 0.69% (136).  
Table III: Coconut Oil Composition (137).  
 
Saturated  g/100g edible 
portion 
Percentage of 
whole oil 
Fatty acid name 
6:0 0.6 0.64% Capronic acid 
8:0 7.5 8.0% Caprylic acid 
10:0 6.0 6.4% Capric acid 
12:0 44.6 47.4% Lauric acid 
14:0 16.8 17.9% Myristic acid 
16:0 8.2 8.7% Palmitic acid 
Monounsaturated    
18:1 5.8 6.2% Oleic acid/Omega 
9 fatty acid 
Polyunsaturated     
18:2 1.8 2.0% Linoleic/Omega 6 
fatty acid 
Lauric acid is a 12 carbon saturated fatty acid that makes up the majority of fatty 
acids in tropical oils like coconut and palm oils (135). Triacylglycerols in coconut oil 
contain 54.3% of lauric acid in the sn-1 or sn-3 position, and 44.1 % in the sn-2 position, 
which leads to a faster absorption rate compared to long chain fatty acids. Lipases 
hydrolyze medium chain fatty acids in the sn-1 and sn-3 positions faster than long chain 
fatty acids. The first step of the triacylglycerol break down forms 1,2-diglycerides and 
free fatty acids, further hydrolysis creates 2-monoglyceride and a free fatty acid, then 2-
monoglyceride undergoes isomerization to become 1-monoglyceride. The triacylglycerol 
in the sn-2 position goes through hydrolysis to create glycerol and free fatty acid. The 
free fatty acid and monoglyceride can be absorbed through the intestine capillaries by 
carrier proteins or passive diffusion (138,139). Lauric acid diffuses freely without the 
help of the carnitine shuttle into the mitochondrial membrane. The free fatty acids are 
then transported mainly through the portal vein straight to the liver or attach to 
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chylomicrons and go through the lymph vessels (139). A study by Bragdon et al. looked 
at the fatty acid composition of olive oil, cod liver oil, and coconut oil in rats and found 
that only 15-55% of lauric acid from coconut oil is absorbed by the lymph while the rest 
is absorbed through the portal system and then less than 5% was found in feces (140) 
Another study by Goransson explained that the faster absorption rates of medium chain 
fatty acids from the blood have to do with their high solubility in water. Lauric acid is 
less hydrophobic and more polar than other fatty acids. Lauric acid disappeared the 
quickest from blood samples of rats injected with lauric acid, myristic acid, and palmitic 
acid (141). Palmitic acid is the major saturated fat consumed by Americans, so 
cholesterol raising effects found in a high saturated fatty acid diet could be due to this 
particular type of fatty acid and not from lauric acid (142).  
Metabolism. Coconut oil is made of mostly medium chain fatty acids, and these 
are metabolized differently from other fatty acids. Medium chain fatty acids are absorbed 
through the lumen in the intestinal mucosa and travel through the portal vein to the liver, 
they do not enter degradation or re-esterification, they bypasses the lipoprotein lipase 
regulated metabolic pathway and are not deposited in adipose tissues, which mean they 
provide readily available form of energy (137,143).  Unlike long chain fatty acids, 
medium chain fatty acids do not participate in the transport of cholesterol, they do not 
need pancreatic lipase, or carnitine acyltransfereanse for transport and absorption, they 
are not carried by chylomicrons to eventually undergo beta oxidation in the liver to create 
cholesterol or triglycerides (137). A randomized, double blind trial measured fatty acid 
metabolism among 10 healthy subjects by comparing an intervention fat formula of 72% 
medium chain fatty acids and 22% omega 3 long chain polyunsaturated fatty acids in a 
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1,500 kcal/day diet with 55.5% of energy being fat. The placebo fat formula was 
vegetable oils composed of mainly long chain fatty acids. Each formula contained 82.8 
kcal or 9.2 grams of total energy coming from fat. The lipid profile of blood plasma was 
evaluated and the change in cholesterol concentration decreased in the intervention group 
by -44.6 mg/dL from baseline to day 15, while the placebo group only had a change of -
22.2 mg/dL. Triacylglycerol in plasma had a change of -77 mg/dL in the intervention 
group, while the placebo group had a change of -12.4 mg/dL. Generally dietary fat has an 
inability to promote fat oxidation, but medium chain fatty acid are absorbed and 
metabolized in a way where fatty acid oxidation, and hepatocellular beta oxidation is 
stimulated creating rapid fat release in the blood (143).  
Health Effects. Virgin coconut oil has a higher polyphenol content compared to 
refined coconut oil, which helps prevent the oxidation of LDL. Polyphenols trap reactive 
oxygen in plasma and interstitial fluid preventing LDL oxidation. The polyphenols and 
tocopherols could also play a role in preventing carbonyl formation of LDL (144). A 
study on rodents compared the polyphenol effects of virgin coconut oil compared to 
copra oil. The total polyphenol content of virgin coconut oil given to the rats was around 
80mg/100g of oil, while copra oil had around 65mg/100g of oil. Rats given the virgin 
coconut oil ended up having higher HDL cholesterol concentrations, lower LDL 
cholesterol concentrations, total cholesterol, triglycerides, and phospholipids in serum 
and tissues such as the liver, heart and kidneys than the group given copra oil. Anti-
oxidative properties of the polyphenols from the virgin coconut oil and copra oil on 
copper induced LDL cholesterol oxidation were measured as well. Virgin coconut oil had 
a significant impact on preventing LDL cholesterol oxidation compared with copra oil 
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and had around a 90% inhibition rate on carbonyl formation during the copper induced 
LDL oxidation compared with around a 80% inhibition rate from copra oil (134). This 
may be due to a higher amount of unsaponifiable components in the virgin coconut oil, 
which keep tocopherols and phytosterols intact. A separate study found the 
unsaponifiables in coconut oil to be 0.5% and squalene in oil to be 16 ug/g of oil (145). 
Squalene is an isoprenoid compound, composed of two or more hydrocarbons, involved 
in the metabolism of cholesterol and protects against lipid peroxidation (146). The total 
phenolic content (mg GAE/100g oil) ranged from 7.9% to 29.2% among virgin coconut 
oil and 6.1% for refined coconut oil. The total antioxidant activity ranged from 49.8% to 
79.9% for virgin coconut oil and 49.6% for refined coconut oil. This difference in virgin 
coconut oil and refined coconut oil antioxidant concentrations could be caused by the 
process of heating during the refining process (136). The more polyphenol substance in 
the oil the more antioxidant activity, which can help reverse cholesterol transport and 
reduce cholesterol absorption in the intestines and overall lower cholesterol.  
History of Coconut Oil and Medicinal Effects. Historically coconut oil has been 
used in larger quantities in places like the Pacific Islands, Asia, and India, and the East 
Indies even calls it green gold (147). Indonesia produces the most coconuts followed by 
India, Brazil, and Sri Lanka (132). These communities have used coconut oil for cooking, 
medicinal, and cosmetics reasons for many years (148). In Sri Lanka the coconut is 
known as the Tree of life and makes up about 80% of their total fat intake (149). Most 
households in Sri Lanka have about 20% of total energy coming from fat, with 70% from 
coconut alone. Coconut contributes to a large part of fat intake for all socio economic 
classes. Lower class levels are receiving about 69-71% kcal of what the Food and 
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Agriculture Organization (FAO) and World Health Organization (WHO) suggest (150). 
A study examining the diet of 60 individuals in the central province of Sri Lanka found 
the mean average energy intake to range from 1902 kcal/day in a low coconut fat diet to 
2018 kcal/day in a high coconut fat diet (151). About 274 kcal/day would be coming 
from just coconut. According to the Demographic Yearbook of the United Nations, Sri 
Lanka had the lowest death rate from heart disease in 1978, but has increased in recent 
years (152).  
After the mid 1940s coconut oil increased in international trade, but then 
decreased in 1987 when this tropical oil fell under scrutiny by certain companies and 
researchers such as the American Soybean Association and American Medical 
Association for being linked to heart disease (153). During this time replacing saturated 
fat with polyunsaturated fat was recommended as well as encouraging food 
manufacturers to discontinue to the use of tropical oils in their food products (153). In the 
U.S. around 2002 the National Academy of Science’s Institute of medicine found trans 
fats to increase low density lipoprotein, which prompted the FDA to start requiring trans 
fats to be in nutrition labels in 2006 (154). According to the World Health Organization 
the world coconut oil consumption increased from around 3.3 million metric tons in 2008 
to over 3.8 in 2009 (155). 
Animal Studies. Several studies involving rodents have investigated the effects of 
coconut oil on blood lipid parameters. A study done by Nevin et al. examined blood lipid 
concentrations of Male rats given 8g/100g weight of virgin coconut oil, copra oil, or 
ground nut oil after a 45 day feeding period. Serum cholesterol between rats fed ground 
nut oil and virgin coconut oil had a difference of 15.9mg/dL, and the difference of 
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14.7mg/dL between copra oil and virgin coconut oil. Virgin coconut oil displayed the 
lowest concentrations of cholesterol in serum, liver, and the heart. Virgin coconut oil had 
higher concentrations of HDL, and lower concentrations of LDL and VLDL compared to 
copra oil and ground nut oil as well (134). Bird carcasses and their serum lipids were 
examined in a separate study, where four intervention diets of soybean oil was replaced 
with either 25%, 50%, 75%, or 100% coconut oil. After 42 days, serum lipids showed 
total cholesterol to HDL ratio in the 100% coconut oil diet to be 1.27mg/dL compared to 
1.33mg/dL for the control group containing only soybean oil. The total cholesterol to 
HDL ratio for 75% coconut oil was the lowest at 1.2mg/dL (156). A study on rats 
compared the lipid parameters between groups fed either coconut oil or soybean oil. Rats 
fed 20% coconut oil after six weeks had a total cholesterol score of 3.6mg/dL and an 
HDL cholesterol of 1.8mg/dL, while those fed 20% soybean oil had a total cholesterol of 
2.8mg/dL and an HDL cholesterol of 1.6 mg/dL (157). A separate study involving 
different dosages of coconut oil ranging from 1ml/day, 2ml/day, and 4ml/day were 
administered to three groups of five pregnant rats for 20 days, while the control group 
was given tap water. Student’s t-test showed no significant difference in total cholesterol 
and triglyceride concentrations between control and intervention groups (158).  
Epidemiological Studies. One longitudinal study in the Philippines that started 
back in 1983 has current records from 2005 that looked at 1,896 women between the ages 
of 25-69. Of those 1,839 were not pregnant or on any lipid lowering medication. Coconut 
oil was measured using two different 24 hour food recalls and was estimated to be about 
9.54 grams/day in the 92% of women who used coconut oil in their cooking. Among the 
low coconut oil intake group the mean HDL was 39.3mg/dL and the high coconut oil 
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intake group had a mean HDL of 42.4mg/dL. Total cholesterol to HDL cholesterol ratio 
was 4.8mg/dL in the low coconut oil intake group compared to 4.8mg/dL in the high 
coconut oil intake group (159). The Tokelau island migrant study followed Polynesian 
immigrants in New Zealand that had migrated from Tokelau 7.1 years prior. Men who 
had migrated to New Zealand in 1966 had higher concentrations of LDL cholesterol, 
triglycerides, and lower concentrations of HDL cholesterol compared to the original 
Tokelau men. The Tokelau population consumed around 53% kcal from a diet rich in 
coconuts, while the immigrants in New Zealand decreased their intake in coconut 
consumption and cholesterol concentrations increased. In 1977, 24-hour dietary food 
recalls and blood samples were collected from randomly selected families, 808 
participants in Tokelau and 1217 participants in New Zealand. Saturated fat energy 
among Tokelau participants averaged to about 45% compared to 21% among New 
Zealand participants. Total cholesterol average from male participants in Tokelau ages 
15-84 was 182.1mg/dL and 198.5mg/dL for those in New Zealand. HDL cholesterol was 
49.9mg/dL for Tokelau women and 47.6mg/dL for men, while New Zealand women had 
an average HDL cholesterol of 48.8mg/dL and men had an average of 45.2mg/dL. LDL 
cholesterol average in Tokelau men was 119.3mg/dL and 132.6mg/dL in New Zealand 
men. The Tokelau dietary studies that took place between 1968 and 1976 found the mean 
energy intake from three points of time was around 1770 kcal/day. Total fat energy 
consumed was about 51% kcal, and of that about 46% kcal came from just saturated fat, 
so about 415 kcal/day of saturated fat. Compared to Tokelau, where coconut, taro and 
breadfruit are the staple foods consumed, New Zealand has replaced these with bread and 
potatoes since they are cheaper (160).  
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Intervention Trials. Randomized controlled studies in humans have investigated 
the effects of coconut oil (CO) on waist circumferences and plasma lipids. A study done 
in Brazil tested the effects of CO supplements verses soybean oil supplements on a group 
of 40 women, between the ages of 20-40, over a 12-week period. Subjects followed a 
hypocaloric diet and were instructed to walk 50 minutes each day. Their exclusion 
criteria included pregnant women, subjects with a BMI over 35 kg/m2, or women with 
hypertension or chronic diseases. Baseline data showed the mean HDL of half the group 
taking 30ml CO (14% kcal of CO from 1,893 kcal mean diet) to be 45.5 mg/dL and 
increased to 48.7 mg/dL by the end of the 12 weeks. There was a 3.2 mg/dL change 
within the CO group as well as a 9.7 mg/dL change between the soybean oil group 
(soybean oil decreased HDL by -6.5mg/dL). The total cholesterol to HDL ratio went 
from 4.23 to 4.06 (161). A separate study at Texas A&M University followed 19 free-
living men with an average age of 26 years for 5 weeks. Two meals were made for each 
participant and containing 15% of protein, 50% of carbohydrates and 35% fat. The test 
fats made up 60% of the total fat and their meals had a mean of 3,400 kcal/day (21% of 
kcal or 714 kcal from CO each day). They tested beef fat, CO, and safflower oil. The 
baseline HDL for CO was 45 mg/dL and this increased to 46 mg/dL by the end of the 5 
weeks. HDL concentrations from beef fat and safflower oil dropped from 44 mg/dL(BF) 
and 42 mg/dL(SO) to 40 mg/dL for both. HDL increased by +6mg/dL between these 
groups. The total cholesterol to HDL ratio went from 3.51 to 3.73 (162). The third study 
looked at the plasma lipids and lipoproteins among 41 Pacific Islanders in New Zealand 
for a 6-week study. The age ranged from 19 to 72 and they provided 39g or 17.5% kcal 
from butter, CO or safflower from a 8.4MJ/d diet (2,007kcal/day diet). The change in 
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HDL increased by 5.8 mg/dL between groups and 4.25mg/dL within the CO group (HDL 
rose from 42.5 mg/dL to 46.8 mg/dL in CO group. The total cholesterol to HDL ratio 
went from 5.01 at baseline to 4.52 (163). A recent study in 2015 by Cardoso et al. 
examined the effects of a diet high in coconut oil on lipid profiles in patients between 45-
85 years of age on secondary prevention of coronary artery disease. Out of 136 eligible 
patients 92 finished the study in the coconut oil group and 22 finished in the diet group. 
The coconut oil group received 13mL each day for six months and serum HDL 
concentrations had a positive change of +3.1 mg/dL while the diet group had a negative 
change of -1.2 mg/dL in serum HDL. The P value was less than 0.01 for the HDL scores 
and found statistically significant. There were no changes in total cholesterol, LDL 
cholesterol and triglycerides (164). A separate randomized control study in 2015 
measured blood lipid markers among men and women ages 18 to 50. Fourteen 
participants had no dietary change while 21 replaced their normal cooking oils with 
coconut oil for a span on four weeks. There was a negative change in HDL by -9.67 
mg/dL in the control group and a positive change of +3.09 mg/dL in the virgin coconut 
oil group. Total cholesterol had a positive increase of +0.77 mg/dL in the control group 
and a negative drop of -0.77 mg/dL in the virgin coconut oil group, except these results 
were found not significant based on a P value above 0.05 for total cholesterol and HDL 
scores. (165).  
Coconut oil being a saturated fat has been vilified and claimed to increase the risk 
of atherosclerosis and heart disease, but it’s unique composition of fatty acids allows it to 
be metabolized differently than other saturated fats. In fact, consuming coconut oil had a 
positive effect on blood lipids in some human and animal randomized trials.  
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Chapter 3 
METHODS 
Subjects and Study Design. This 8-week study was a randomized placebo 
controlled trial. Healthy adults, free from chronic disease, between the ages of 18 and 40 
were recruited through Arizona State University (ASU) ListServs. Interested subjects 
were referred to an online survey (www.surveymonkey.com) to determine eligibility 
based on physical activity (Inactive: does not meet the U.S. guidelines, <150 minutes of 
moderate exercise in a week), smoking habits (non smoking), self reported 
anthropometric measurements (22-35 kg/m2 Body Mass Index, BMI), non pregnant or 
lactating women and ability to meet at Arizona State University’s downtown campus on 
3 separate occasions. The exclusion criteria is based on the use of prescription 
medications that may interfere with blood lipids, corticosteroids, diabetes drugs, statins, 
thyroid medications, non steroidal anti inflammatory drugs, and taking birth control less 
than three months. Participants were recruited starting September 2015 after Arizona 
State University Institutional Review Board (IRB) approval and qualified based on age 
and BMI. Eligible subjects were contacted to schedule a screening visit (study visit 1). 
All participants provided written consent (see Appendix-A).  
  At screening visit (study visit 1) eligible participants were asked to complete a 
health history questionnaire, and validated physical activity questionnaire and HDL 
measurements were collected via fingerpick. Baseline anthropometric measurements, 
including weight, height, waist circumference, and percent body fat will were measured. 
Height and weight were measured using a stadiometer and bioelectrical impedance scale, 
(Tanita, Tanita corporation of America, Inc. Arlington Heights, Illinois).  
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 Participants who qualified were stratified based on age, BMI, weight, and HDL 
then randomly assigned to the treatment group (CO) or the control group (CON). An 
online randomizer was used to group the subjects. Participants were then asked to record 
their daily food intake on a food log 1 week before the start of the study to evaluate the 
typical saturated fat and caloric intake.  
 During the baseline study or week 0 (study visit 2), supplements were distributed 
using a double-blind procedure. Subjects received either a placebo capsule of all purpose 
white flour or coconut oil capsule (Puritan’s Pride, coconut oil softgels, 2g each, see 
Appendix-D). Subjects were instructed to ingest 2 capsules in the morning, preferably 
with food. Participants were instructed not to adjust their diet or physical activity during 
the 8 week trial. A validated mood questionnaire was collected during this visit, along 
with a fasting blood sample, weight, BMI, percent body fat from the Tanita, and waist 
measurements, as well as Dual-energy X-ray absorptiometry (DEXA) scans. A $10 
Target gift card incentive was distributed to participants. Compliance calendars were 
given to each participant to record through capsule intake on a calendar check-off system 
as well as a dietary food log for a record of subject’s three day intake before their 
scheduled last visit. Subjects were asked to write two check marks for two capsules taken 
each day, and leave days blank when capsules were not taken. Biweekly email reminders 
were sent to all subjects to keep up compliance to the study protocol. 
 On the last visit or week 8 (study visit 3) weight, percent body fat, BMI, waist 
circumferences, validated mood questionnaire, physical activity questionnaire (metabolic 
equivalent of task, MET), dietary food logs, compliance calendars, left over capsules and 
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fasting blood samples were collected during this visit and a $15 Target gift card incentive 
was administered (see Appendex-B).  
 To determine sample size, a power analysis was calculated using a probability of 
0.05 and a power of 0.8 as well as a verified sample size calculator. The average standard 
deviation was 4.9 mg/dL from previous studies (161,162,163) testing dietary 
supplementation on HDL, with an average expected change of 4.8 mg/dL, yielding a 
calculated sample size of 36. Forty-two participants were enrolled in the study (see 
Appendix-C).  
Blood Measures. Fifteen milliliters of plasma blood samples were collected in 
green top tubes (Li-Heparin) with Ethylenediaminetetraacetic acid (EDTA) as an 
anticoagulant. Within 30 minutes of collection, samples were labeled, pipetted, and 
centrifuged at 1000 x g for 15 minutes. The plasma was separated and stored at -80 
degrees F until ready for analysis. HDL was tested in COBAS.  
Statistical analysis plan. Statistical analyses were conducted using SPSS Version 
23.0 software (SPSS, Inc., Chicago, IL, USA). Descriptive statistics were used to 
describe baseline data and compare individuals in both treatment and control groups. An 
independent T-test was conducted on each dependent variable to determine the mean 
difference between the intervention and control groups. Data were examined for 
normality using Shapiro-Wilk test and transformed if necessary. Participants were 
considered compliant to the treatment plan if the value is > or equal to 75% for % 
adherence. Data were reported as the means ± SD. P < 0.05 was considered statistically 
significant results. A repeated measures analysis of variance (ANOVA) was used for 
statistical analyses.  
 45 
Chapter 4 
RESULTS 
Recruitment for this trial took place in October 2015 and the 8-week intervention 
was completed in December 2015 at Arizona State University’s downtown Phoenix 
campus. An online survey was administered through Listserv, flyers, and media posts. 
Out of 154 respondents who completed the survey, 74 were excluded and the remainders 
(n=80) were invited to the screening visit. Forty-two respondents came to the screening 
visit and provided written consent. One participant revealed that she had started to smoke 
cigarettes since completing the online survey and was thus excluded. Two additional 
subjects withdrew because of scheduling conflicts with school or work or the morning 
blood fasting collection time. The 39 subjects were stratified by age, gender, and BMI 
and randomized to the experiment (CO) group (n=19) or the control (PL) group (n=20). 
Of the 39 subjects who started data collection, 32 subjects finished the third visit and 
final data collection 14 and 18 for CO ad PL respectively. The 7 participants who did not 
complete the 8-week trial were lost to attrition. Seven men and 25 women completed the 
study and were used for data analysis. There was an 89.8% adherence in the CO group 
and an 87.9% adherence in the PL group throughout the 8 weeks. Subject adherence was 
verified using a compliance calendar. Additionally 3-day food logs were collected at visit 
2 and 3 to track dietary consumption throughout the 8-week trial.  
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Table 4 Baseline Characteristics by Group* 
 
* Statistical analyses were performed using the SPSS Statistical Analysis system 23.0. 
CO – Coconut oil group; PL – Placebo group. Adherence represents % of days pills 
consumed. Before statistical analysis was run, normal distribution and homogeneity of 
the variances were tested. Significant differences between groups was defined as P < 
0.05. Data are expressed as mean ± standard deviation. 
 
Screening variables such as age, height, weight, waist METS (kcal/kg/wk), body 
mass index (BMI), and fat percentage were measured upon the first visit and were 
analyzed using independent samples t-tests, which showed no significant differences 
between CO and PL groups at baseline (Table 1). Age ranged from 18 to 38 years with a 
mean age of 25.1 ± 5.7 years for CO group and 24.2 ± 5.3 years for the PL group. 
Baseline weight for both groups ranged from 104.6 pounds to 212.4 pounds. Height for 
both groups ranged from 57.5 inches to 72.0 inches. Waist circumference in both groups 
ranged from 26.5 inches to 42.0 inches. Metabolic equivalents (METS) for both groups 
ranged from 26 to 119 kcal/kg/week. BMI in both groups ranged from 18.4 to 34.3 
kg/m2. Body fat percentage in both groups ranged from 13.3% to 45.7%. Confounders for 
LDL cholesterol included METS (p=0.047) and BMI (p=0.014). Confounders for total 
cholesterol included BMI (p= 0.038) and fat percentage (p=0.013). The only confounder  
 CO PL P value 
N (M) 14 (4) 18 (3)  
Age (years) 25.1± 5.7 24.2± 5.3 0.643 
Height (inches) 65.2± 3.4 65.5± 3.6 0.801 
Weight (pounds) 142.6± 31.9 150± 29.8 0.501 
Waist (inches) 30.9± 3.8 32.6± 4.6 0.278 
METS 
(kcal/kg/wk) 
59.6± 15.8 47.9± 22.8 0.113 
BMI (kg/m2) 23.5± 4.5 24.5± 4.1 0.519 
Body fat (%) 24.1± 8.9 28.7± 7.4 0.120 
Adherence (%) 89.8± 11.8 87.9±8.2 0.595 
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for HDL cholesterol was gender (p=0.009). Total weight did not change within the 
coconut oil and placebo groups (p=0.886). Physical activity decreased over the trial 
(p=0.023), but there were no differences between groups over the course of the study 
(p=0.472).  
Table 5 Blood Cholesterol Levels by Group*  
* Outcome variables did not differ significantly at baseline. Confounders were controlled 
for in the analyses. P value represents repeated measures ANOVA to determine the 
effects of treatment on outcome measures. Data are expressed as mean ± standard 
deviation. Significant differences within or between groups was defined as P < 0.05. A 
large effect size (partial ETA2) was defined as ≥0.14. 
 
Blood sample data are available for the remaining 32 subjects from visits 2 and 3 
and outcome variables including HDL, LDL, Total Cholesterol, Triglycerides, and Total 
Cholesterol/HDL ratio did not differ significantly at baseline (Table 2). For the CO 
supplementation group, the change in HDL (mg/dL) was +2.5 ± 5.6 and the PL group had 
a change of +1.4 ± 6.9 (p=0.648). The change in LDL (mg/dL) in the CO group was +4.4 
± 6.9 and – 1.0 ± 8.1 in the PL group (p=0.247). The change in total cholesterol (mg/dL) 
in the CO group was +7.9 ± 18.9 and +0.6 ± 11.0 in the PL group (p=0.216). The change 
in triglycerides (mg/dL) in the CO group was +1.0 ± 22.4, and -1.4 ± 37.4 in the PL 
 
 Baseline 8 Weeks Change P 
Value 
Partial 
ETA2 
HDL (mg/dL) CO 56.7± 14.0 59.0± 17.2 +2.5± 5.6 0.648 0.014 
 
PL 60.7± 11.0 62.1± 13.2 +1.4± 6.9   
LDL (mg/dL) CO 97.0± 24.6 101.4± 25.3 +4.4± 15.0 0.247 0.041 
 
PL 94.3± 16.8 93.3± 17.0 -1.0± 8.1   
Total Chol 
(mg/dL) 
CO 159.4± 27.5 167.3± 27.3 +7.9± 18.9 0.216 0.036 
 
PL 159.7± 22.2 160.3± 25.3 +0.6± 11.0   
TG (mg/dL) CO 75.4± 21.2 76.4± 27.6 +1.0± 22.4 0.838 0.002 
 
PL 80.6± 44.0 79.2± 38.4 -1.4± 37.4   
Total 
Chol/HDL 
ratio 
CO 2.97± 0.85 3.03± 0.92 +0.1± 0.3 0.369 0.021 
PL 2.69± 0.48 2.65± 0.48 -0.0 ± 0.3   
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group (p=0.369). The baseline total cholesterol to HDL ratio did not differ between 
groups in both the CO and PL groups. Over the course of the trial, there was not a 
significant change in total cholesterol to HDL ratio seen between CO and PL groups 
(+0.1± 0.3 vs -0.0± 0.3, p=0.369) (Table 2).  
 
Figure 1: Comparison of blood lipid concentrations between groups at week 1 and week 
8.  
• Data represent all subjects (n=32) analyzed between groups from week 1 through 
week 8 of the trial. CO= coconut oil group. PL= Placebo group.  
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Figure 2: Comparison of total cholesterol to HDL ratio between groups at week 1 and 
week 8 
• Data represent all subjects (n=32) analyzed between groups from week 1 through 
week 8 of the trial. CO= coconut oil group. PL= Placebo group.  
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Figure 3: Comparison of HDL cholesterol between groups at week 1 and week 8 
• Data represent all subjects (n=32) analyzed between groups from week 1 through 
week 8 of the trial. CO= coconut oil group. PL= Placebo group.  
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Figure 4: Comparison of LDL cholesterol between groups at week 1 and week 8 
 
 
• Data represent all subjects (n=32) analyzed between groups from week 1 through 
week 8 of the trial. CO= coconut oil group. PL= Placebo group.  
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Figure 5: Comparison of triglycerides between groups at week 1 and week 8 
 
• Data represent all subjects (n=32) analyzed between groups from week 1 through 
week 8 of the trial. CO= coconut oil group. PL= Placebo group.  
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Figure 6: Comparison of total cholesterol between groups at week 1 and week 8 
• Data represent all subjects (n=32) analyzed between groups from week 1 through 
week 8 of the trial. CO= coconut oil group. PL= Placebo group.  
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Chapter 5 
DISCUSSION  
 This randomized, double-blind, placebo-controlled 8 week trial represents a blood 
lipid comparison between healthy individuals taking a 2 gram/day coconut oil 
supplement versus a control group. The biomarkers examined included total cholesterol, 
LDL cholesterol, HDL cholesterol, and triglycerides. Findings indicate there was no 
significant change in the total cholesterol to HDL cholesterol ratio from consuming 
coconut oil. Research testing the efficacy of coconut oil is limited, but this saturated fat 
has been shown to positively influence blood lipid concentrations in some animal and 
intervention trials, although this was not shown in this current study 
(134,156,157,161,162,163,164).  
 The length of time of this study could be a limiting factor, since 8 weeks might be 
considered a relatively short time for any significant changes to occur. Previous studies 
that have been done in humans and animals observing the effects of coconut oil on lipid 
parameters have been short time periods between 20 days to 12 weeks with the average 
around 6 weeks and one single study lasting 6 months. The study by Cardoso et al. 
showed statistically significant data for increased HDL concentrations after six months, 
while the shorter study done in 4 weeks by Webb et al. showed no significant changes in 
HDL or total cholesterol (164,165).  
Another limiting factor are studies that used hydrogenated coconut oil versus 
virgin coconut oil, which was found to have higher amounts of polyphenols and 
antioxidants. Previous studies that have experimented with coconut oil and found it to 
increase adverse blood lipid concentrations have been judged for using hydrogenated 
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coconut oil and the trans fatty acids associated (159). It is not clear from the intervention 
trials mentioned in chapter 2 if the coconut oil used was in fact non-hydrogenated, but 
this study used organic, non-hydrogenated coconut oil by the supplement brand Puritan’s 
Pride. Puritan’s Pride coconut oil supplements are not USP-verified, 3rd party tested, or 
evaluated by the Food and Drug Administration.  
Dosage differences in each study could account for the conflicting data on the 
effects of coconut oil on lipid concentrations. The coconut oil supplement in this trial was 
2g/day, which was chosen based on the dosage used in previous research in an ASU 
clinical trial using coconut oil as a placebo since a positive change in HDL cholesterol 
was observed. Compared to previous studies, a 2g dosage is exceptionally small. The 
study done on women in Brazil used 30ml of coconut oil a day, or 27.9g (1ml of coconut 
oil is equal to .93g) (161). The New Zealand study had participants taking 39g a day 
(163). The study from Texas A&M University had men take 79.3g of coconut oil a day, 
or 714kcal from a 3,400kcal diet (162). The most recent study by Cardoso et al. had 
subjects taking 13mL or 12.1g of coconut oil a day (164). Compared to these dosages it is 
clear that 2g is way below the average intake in intervention trials, and this could be a 
factor as to why there was no significant findings in the data. The Puritan’s Pride brand 
of coconut oil supplementation recommends 2g/day, which is also another reason for 
testing this dosage. The health effects from this 2g/day dosage would need to be further 
investigated, because it had no significant change in blood lipid concentrations after an 8-
week period.  
The gender differences should be considered since 7 men and 25 women 
completed the study. Forty-four percent of women reported the use of birth control, and 
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while this shouldn’t impact results of the study (given the exclusion criteria included 
women taking oral contraceptives less than three months) oral contraceptives have been 
known to decrease HDL cholesterol in women. One clinical experiment had 26 women 
start on oral contraceptives and compared HDL cholesterol before and after therapy. 
After two months HDL decreased significantly from 56 ± 14.4 mg/dL to 52 ± 12.3 mg/dL 
(166). This could limit the generalizability of the results to women not on birth control, 
the elderly, and males.   
Age could also be a factor, given the average age was 25 years for the coconut oil 
group and 24 for the placebo group. Typically the cholesterol concentrations of this age 
group are at optimal levels and this type of study may not have an effect. Data from a 
study done at University of Minnesota found the average total cholesterol concentrations 
of normal men between the ages of 17-25 years to be 176.7 mg/dL and 210.3 mg/dL at 
ages 30-45 years (167). The average baseline total cholesterol in the coconut oil group is 
159.4 mg/dL, which compared to the ATP III Guidelines, is desirable below 200 mg/dL. 
The average baseline HDL cholesterol in the coconut oil group is 56.7 mg/dL, which falls 
short of the American Heart Association recommendation >60 mg/dL (130,168). There is 
room for improvement in the HDL concentrations, but the results show a non-significant 
change of +2.5 mg/dLin HDL after 8 weeks.  
Some strengths of this study include the screening and inclusion and exclusion 
criteria designed to get a balanced sample of healthy subjects. The inclusion criteria 
included non-smokers, free of chronic diseases, meets the U.S. weekly exercise 
guidelines, BMI between 22-35, between the ages of 18-40, not taking medications 
affecting blood lipids, non lactating or pregnant women, no food restrictions, and not 
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taking birth control less than three months. Investigator bias was also prevented using the 
double blind method to randomize the subjects into groups. Blood draws on participants 
were done during fasting, which helped prevent skewed data.   
The hypothesis states that in free-living healthy adults, 2g/day of coconut oil will 
decrease the total cholesterol to HDL ratio significantly compared to a placebo capsule 
after an 8-week trial with no diet or physical activity modification; according to the data, 
this hypothesis is not supported.  
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Chapter 6 
CONCLUSION AND RECOMMENDATIONS 
Conclusion. The results of this study did not demonstrate a significant change in 
total cholesterol to HDL cholesterol concentrations in individuals taking 2g of coconut oil 
a day for 8 weeks. Blood lipid parameters including total cholesterol, LDL cholesterol, 
HDL cholesterol, and triglycerides were not significantly altered in either direction 
among those in both the coconut oil and placebo groups. Coconut oil does not appear to 
increase HDL cholesterol at a 2g/day dose. The effects of coconut oil on blood lipids and 
CVD risk markers have been researched in previous studies, however more research is 
needed to find the appropriate dosage needed to make a beneficial impact.   
Recommendation. Future research in this area should consider a more diverse 
sample of men and women, extending the length of time for the trial, and increasing the 
dosage to see if blood lipid parameters are altered. By possibly increasing and 
diversifying the sample group, this could be more generalizable to the public. The lack of 
change observed in cholesterol levels could account for the small dosage used in this 
study. More research is needed to assess the current recommended dosage from 
supplement brands and find an optimal and effective dose. Increasing the dosage and 
period of the trial could also achieve more significant results.   
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APPROVAL: EXPEDITED REVIEW 
Carol Johnston 
SNHP: Nutrition 
602/827-2265 
CAROL.JOHNSTON@asu.edu 
Dear Carol Johnston: 
On 9/10/2015 the ASU IRB reviewed the following protocol: 
Type of Review: Initial Study  
Title: Dietary Supplementation and Health  
Investigator: Carol Johnston 
IRB ID: STUDY00003159 
Category of review: (9) Convened IRB determined minimal risk 
Funding: Name: Graduate College 
Grant Title:  
Grant ID:  
Documents Reviewed: • adherence calendar, Category: Other (to reflect 
anything not captured above); 
• consent, Category: Consent Form; 
• protocol, Category: IRB Protocol; 
• mood measure, Category: Measures (Survey 
questions/Interview questions /interview guides/focus 
group questions); 
• online survey, Category: Recruitment Materials; 
• physical activity measure, Category: Measures 
(Survey questions/Interview questions /interview 
guides/focus group questions); 
• health history, Category: Screening forms; 
• flyer, Category: Recruitment Materials; 
• verbal script, Category: Recruitment Materials; 
• diet record, Category: Other (to reflect anything not 
captured above); 
 
The IRB approved the protocol from 9/10/2015 to 9/9/2016 inclusive. Three weeks 
before 9/9/2016 you are to submit a completed Continuing Review application and 
required attachments to request continuing approval or closure.  
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If continuing review approval is not granted before the expiration date of 9/9/2016 
approval of this protocol expires on that date. When consent is appropriate, you must use 
final, watermarked versions available under the “Documents” tab in ERA-IRB. 
In conducting this protocol you are required to follow the requirements listed in the 
INVESTIGATOR MANUAL (HRP-103). 
Sincerely, 
IRB Administrator 
cc:  
Rachel Shedden 
Claudia Thompson-Felty 
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Randomized 
Controlled 
Study 
Length 
of 
Trial: 
Weeks 
Number 
of 
Subjects 
Age of 
Subjects 
Subject 
State 
Dosage of 
coconut oil 
Change in 
HDL 
Change 
in SD 
Calculated 
(n) 
Brazil 12 20 20-40 
(women) 
Healthy, not 
taking 
medications 
that alter 
blood lipids 
on 
hypocaloric 
diet, walked 
50 min/day.  
14% kcal 
(30ml= 
270kcal from 
1,893 kcal/day 
mean diet) 
3.2mg/dL 
Δ within 
CO group 
9.7mg/dL 
Δ between 
groups 
(soybean 
vs. CO)  
4.75 10 
Texas 5 19 26 (men) Healthy, not 
taking 
medications 
that alter 
blood lipids. 
21% kcal (test 
fats make up 
60% of 35% 
of fat from 
total diet. 
714kcal from 
3,400 kcal/day 
mean diet) 
1mg/dL Δ 
within CO 
group 
6mg/dL Δ 
between 
groups  
(Beef fat, 
Safflower 
oil, CO)  
2.0 8 
New Zealand 6 41 19-72 
(men and 
women) 
Healthy, not 
taking 
medications 
that alter 
blood lipids. 
18% kcal (39g 
=351kcal from 
2,005kcal/day 
mean diet) 
4.25mg/dL 
Δ within 
CO group 
5.8 mg/dL 
Δ between 
groups 
(Butter, 
Safflower 
oil, CO)  
4.7 24 
ASU Fish Oil 
Study 
8 42 18-40 
(men and 
women) 
Healthy, not 
taking 
medications 
that alter 
blood lipids. 
No change 
in diet or 
exercise. 
2g= 1% kcal 4.74mg/dL 
Δ within 
CO group  
3.76mg/dL 
Δ between 
groups 
(Fish oil 
and CO) 
8.0 146 
AVERAGE 8 31 18-40 
(men and 
women)  
Healthy, not 
taking 
medications 
that alter 
blood lipids. 
13% kcal  3.30mg/dL 
Δ within 
CO group  
6.32mg/dL 
Δ between 
groups  
Average: 
4.9 
47 
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154	  Respondents	  completed	  the	  survey	  
74	  Excluded	  	   80	  Invited	  to	  screening	  
42	  Respondents	  provided	  written	  consent	  
3	  Excluded	  (scheduling	  conOlict)	   39	  Randomized	  
19	  CO	  group	  
14	  Finished	  89.9%	  adherence	  
20	  PL	  group	  
18	  Finished	  87.9%	  adherence	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HEALTH /HISTORY QUESTIONNAIRE                                ID#___________________ 
 
1. (To be completed by researchers):  Height _________               Weight ________________ 
 
                                                         Percent body fat_____       BMI____________________ 
 
2. Gender:  M    F 
 
3. Age:  __________ 
 
4. Have you lost or gained more than 5 lbs in the last 12 months?         Yes         No 
 
      If yes, how much lost or gained? _________     How long ago? ___________ 
 
5. Education  (please circle)    HS diploma     Fresh.      Soph.     Jr.     Sr.     Grad. 
 
6. Ethnicity: (please circle)  Native American     African-American     Caucasian     
Hispanic     Asian     Other 
 
7. Do you smoke?  No, never ________   
 
                   Yes           ________     # Cigarettes per day = ________        
                        
                               I used to, but I quit _______ months/years (circle) ago 
 
7.  Do you take any medications regularly?     Yes No           If yes, list type and frequency: 
     
Medication    Dosage    Start date and frequency 
of use 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
____________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
___________________________________________________________ 
 
 
8. Do you currently take supplements (vitamins, minerals, herbs, etc.) ?    Yes    No         If yes, 
list type and frequency:                               
     
Supplement    Dosage    Start date and frequency 
of use 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
____________________________________________________________  
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______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
___________________________________________________________ 
 
9.  Have you had test procedures using barium/isotopes in the past 3 months?       Yes 
____    No  _____ 
     If yes, please provide details of the procedure: 
     
________________________________________________________________________
_________ 
 
 
10.  On average, how many minutes per day do you spend at moderate to vigorous 
activity? ____________ 
 
 
 
 
 
 
 
11.   Please ANSWER (YES/NO) if you currently have or if you have ever been 
diagnosed with any of the following diseases or symptoms: 
 
 YES NO  YES NO 
Coronary Heart Disease   Chest Pain   
High Blood Pressure   Shortness of Breath   
Heart Murmur   Heart Palpitations   
Rheumatic Fever   Any Heart Problems   
Irregular Heart Beat   Coughing of Blood   
Varicose Veins   Feeling Faint or Dizzy   
Stroke   Lung Disease   
Diabetes   Liver Disease   
Low Blood Sugar   Kidney Disease   
Bronchial Asthma   Thyroid Disease   
Hay Fever   Anemia   
Leg or Ankle Swelling   Hormone Imbalances   
Eating Disorders   Emotional Problems   
 
Please elaborate on any condition listed 
above.___________________________________________________ 
________________________________________________________________________
________________ 
 
12.  How would you rate your lifestyle? 
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Not active ___________       Active ___________ 
Somewhat active __________      Very Active 
___________ 
 
13.  Please circle the number of times you did the following kinds of exercises for more 
than 15 minutes last week. 
Mild exercise (minimal effort):  Easy walking, golf, gardening, bowling, yoga, fishing, 
horseshoes, archery, etc. 
 
Times per week:     0   1   2   3   4   5   6   7   8   9   10   11  12   13   14+ 
  
Moderate exercise (not exhausting):  Fast walking, easy bicycling, tennis, easy 
swimming, badminton, dancing, volleyball, baseball, etc. 
 
Times per week:     0   1   2   3   4   5   6   7   8   9   10   11  12   13   14+ 
  
Strenuous exercise  activities (heart beats rapidly):  Running, jogging, hockey, football, 
soccer, squash, basketball, cross country skiing, judo, roller skating, vigorous swimming, 
vigorous long distance bicycling, etc. 
 
Times per week:     0   1   2   3   4   5   6   7   8   9   10   11  12   13   14+ 
 
14.  How much alcohol do you drink? (average drinks per day)  ___________ 
 
15.  Do you have any food allergies?          Yes    No       If yes, 
explain:________________________________________ 
 
16.  Are there any foods that you will not consume?     Yes    No    If yes, please list 
______________________________ 
 
______________________________________________________________________________
____________________ 
 
17. Do you follow a special diet? (weight gain/loss, vegetarian, low-fat, etc.)  Yes    No        
              
     If yes, explain:  
______________________________________________________________________________
____ 
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Exit this survey  
ASU Dietary Supplement Study  
Thank you for your interest in this research study conducted by Dr. Carol 
Johnston, ASU nutrition professor, and Claudia Thompson-Felty, a 
nutrition doctoral student. This survey will ask questions to determine if 
you may qualify for this study. You may quit the survey at any time if you 
do not want to continue answering questions. If you complete the survey, 
you will be contacted via email and told whether you qualify for the study. 
If you wish to continue to participate in the recruitment process, you can 
reply to the email. If you have any questions, please contact Dr. Johnston, 
ASU Nutrition Professor, at carol.johnston@asu.edu. Information 
collected from this survey may be used in research reports in aggregate 
form only. 
 
Thank you for your interest in research conducted in the School of 
Nutrition and Health Promotion.  
* 1. Please provide your email address  
   
* 2. Please select your gender  
  Male  
  Female  
* 3. What is your age?  
Age (years) 
   
* 4. Please enter your height and weight  
Height (inches) 
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Weight (pounds) 
   
* 5. Do you have (or think you have) food allergies (such as peanut or gluten)?  
  Yes  
  No  
* 6. Are you following a special diet (such as vegetarian or gluten-free)?  
  Yes  
  No  
If yes please specify: 
   
* 7. Do you take any dietary supplements?  
  Yes  
  No  
If yes (please specify) 
   
* 8. Do you take any of the following prescription medications: corticosteroids, 
diabetes drugs, statins, thyroid medications, non steroidal anti inflammatory drugs, 
blood pressure drugs, antipsychotics/mood disorder drugs, antidepressants, 
seizures/mood stabilizers  
  Yes  
  No  
* 9. If female, are you pregnant, lactating, or do you anticipate becoming pregnant?  
  Yes  
  No  
* 10. If you smoke, please select how many cigarettes you smoke per day  
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  0  
  1-5  
  6-10  
  >10  
* 11. How many minutes per week do you participate in moderate or highly intense 
exercise?  
   
* 12. Will you be able to maintain your current diet and physical activity patterns 
for a consecutive 8 weeks?  
  Yes  
  No  
* 13. Are you willing and able to travel to the ASU Downtown Campus to meet with 
research investigators on three separate occasions?  
  Yes  
  No  
* 14. Are you willing to fast overnight and provide a morning blood sample on 2 
occasions during this study?  
  Yes  
  No  
* 15. Are you willing to have two dexa scans (radiation level 1/10 that of a chest x-
ray) to determine body fat composition?  
  Yes  
  No  
Done  
      
 
